Stability of methylnicotinate in aqueous solution as utilized in the 'niacin patch test'
© Ross and Katzman; licensee BioMed Central Ltd. 2008
Received: 09 April 2008
Accepted: 24 September 2008
Published: 24 September 2008
The topical application of methylnicotinate results in a localized vasodilatatory response which has been found to differ from that observed to occur in healthy controls in a variety of medical conditions. The stability of the drug in aqueous solution is unclear while difficulties can be encountered when preparing methylnicotinate solutions for this purpose. To aid in the determination of how long solutions of the drug should be stored before discarding we have used a collection of aged batches of methylnicotinate to determine the stability of the drug in aqueous solution.
The degradation of methylnicotinate was determined in batches which had been stored at 4°C for between 5 and 1062 days prior to analysis by High Performance Liquid Chromatography. The major degradation product of methylnicotinate was nicotinic acid which formed at an approximate rate of 0.5% of the starting methylnicotinate concentration per annum. Furthermore, the ability of methylnicotinate solutions of different ages to induce vasodilatation was assessed in healthy volunteers. No significant difference in vasodilatatory response was apparent between batches which had been stored for between zero and 1057 days.
Methylnicotinate exhibits excellent chemical and biological stability in solution facilitating its use in clinical applications.
Systemic administration of the B vitamin niacin (nicotinic acid) produces a generalized vasodilatatory response . This occurs due to nicotinic acid stimulating the production of prostaglandin D2 from arachidonic acid in the skin which subsequently acts upon capillary endothelial cells to cause vasodilatation [1, 2]. The methylester of nicotinate, methylnicotinate, has a similar vasodilatatory effect, however the ester can be applied transcutaneously resulting in a localized, rather than generalized, response . Methylnicotinate has found application as a rubefacient  and in the development and testing of anti-inflammatory drugs . Topical application of methylnicotinate has also been used to investigate the inflammatory response in a variety of disorders including autism , Huntington's disease , social phobia , major depressive disorder [9, 10] and schizophrenia [3, 10–18]. In this latter application varying doses of methynicotinate are applied to the skin (normally the forearm) in the form of a patch (frequently, if inaccurately, referred to as a 'niacin patch'). The resulting vasodilatatory response is then measured either by the visual estimation of erythema [4, 9] or measuring superficial blood flow by laser Doppler spectrometry [8, 13, 14]. Such studies have been complicated by the fact that the stability of methylnicotinate in aqueous solution is unknown, necessitating the preparation of new solutions on a regular basis. Besides introducing an additional source of error, the production of new batches of the drug is made difficult due to the high degree of hygroscopicity of solid methylnicotinate. This results in storage and handling difficulties and an inevitable need to regularly discard batches of the solid ester. It would therefore be beneficial to store the aqueous solution for extended periods of time. The stability of methylnicotinate in aqueous solution is not known however, and hence it is unclear for how long the solutions can be stored for. As such many batches of the aqueous drug have been prepared and stored over several years. This has allowed us to investigate the stability of methylnicotinate in solution as well as testing the effect of storage time on the ability of aged preparations to induce erythema, as an aid to determining the storage life of the solution.
Analysis of methylnicotinate degradation in aqueous solution
Methylnicotinate (NHS Highland Labs, UK) was prepared at a concentration of 1 M in water and stored at 4°C in glass containers for between 5 – 1062 days prior to analysis. All batches were prepared using an identical protocol in the same laboratory. No differences in colour or clarity were discernable by visual inspections between batches of different ages, and no batches contained any visible precipitate. The chemical stability of methylnicotinate was investigated using High Performance Liquid Chromatography (HPLC). To accomplish this 1 M stock solutions of methylnicotinate were diluted and methylnicotinate and a degradation product, nicotinic acid, determined in quadruplicate by HPLC using the following analysis parameters: injection volume: 20 μL; separator column: Supelco (Sigma, UK) supelcosil TM LC-18 ODS-18, (length: 25 cm, internal diameter: 4.6 mm, particule size: 5 μm); eluant: 25% v/v methanol in water; eluant flow rate: 1.5 mL/min. Eluted compounds were detected by UV @ 263 nm using an Applied Biosystems Spectroflow 757 UV-vis detector and quantified by comparision with nicotinic acid and 6-methylnicotinate standards (Aldrich, UK). Nicotinic acid had a retention time of 1.4 minutes and a limit of detection of 0.04 μg/ml, while methylnicotinate exhibited a retention time of 7.3 minutes and a limit of detection of 0.05 μg/ml. Within-day variance expressed as the standard deviation as a percentage of the mean was 0.8%, and between day variance was 1.5%. The detection of both nicotinate and methylnicotinate showed a linear response with respect to concentration (Pearson correlation coefficient of detector response vs. applied quantity was 0.98) over the range tested using freshly prepared standards (maximum concentration tested was 150 μg/ml).
Our data suggests that the degradation of methylnicotinate proceeds slowly in aqueous solution. Chromatographic analysis indicates that the methylester gradually hydrolyses at the rate of approximately 0.5% per annum to form nicotinic acid and, presumably, methanol. No other degradation products were noted. This rate of degradation had no apparent effect upon the ability of aged batches, prepared up to approximately 3 years prior, to induce erythema in healthy subjects. Since erythema was determined visually it remains a possibility that detection methods which are able to detect smaller changes in blood flow, such as laser Doppler spectroscopy, would have detected an effect of storage time. Such a possibility is unlikely, however, given that the extent of degradation in batches prepared 1062 days prior (approximately 1.5%) is rather lower than the test-retest variance of laser Doppler measurements which are in the range of 5 – 10% (BMR, unpublished observations). It is important to note that the methylnicotinate solutions used in this study had a concentration of 1 M and had been stored refrigerated at 4°C in glass containers. It is possible that storage of solutions at different concentrations, or in containers made from substances other than glass would have given contrary results due to, for example, absorption to the surface of the container. Moreover, storage at higher temperatures e.g. room temperature would likely have resulted in higher rates of degradation, although it is common for test reagents to be stored in a refrigerator. Nevertheless, our overall conclusion is that methylnicotinate solutions can be stored for extended periods of time at 4°C in glass containers without the occurrence of extensive chemical degradation or loss of biological activity. This finding may aid the use of methylnicotinate for research purposes or for future clinical diagnostic uses.
This work was funded by a grant from the European Union Development Fund to BMR. The funding agency had no role in the design of the study or in the writing of the manuscript.
- Morrow JD, Parsons WG, Roberts LJ: Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins. 1989, 38: 263-274. 10.1016/0090-6980(89)90088-9.View ArticlePubMedGoogle Scholar
- Morrow JD, Awad JA, Oates JA, Roberts LJ: Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J Invest Dermatol. 1992, 98: 812-815. 10.1111/1523-1747.ep12499963.View ArticlePubMedGoogle Scholar
- Ward PE, Sutherland J, Glen EM, Glen AI: Niacin skin flush in schizophrenia: a preliminary report. Schizophr Res. 1998, 29: 269-274. 10.1016/S0920-9964(97)00100-X.View ArticlePubMedGoogle Scholar
- Caselli A, Hanane T, Jane B, Carter S, Khaodhiar L, Veves A: Topical methyl nicotinate-induced skin vasodilation in diabetic neuropathy. J Diabetes Complications. 2003, 17: 205-210. 10.1016/S1056-8727(02)00256-8.View ArticlePubMedGoogle Scholar
- Jumbelic LC, Liebel FT, Southall MD: Establishing a minimal erythema concentration of methyl nicotinate for optimum evaluation of anti-inflammatories. Skin Pharmacol Physio. 2006, 19: 147-152. 10.1159/000092595.View ArticleGoogle Scholar
- Puri BK, Singh I: Normal phospholipid-related signal transduction in autism. Prog Neuropsychopharmacol Biol Psychiatry. 2002, 26: 1405-1407. 10.1016/S0278-5846(02)00303-2.View ArticlePubMedGoogle Scholar
- Puri BK: Impaired phospholipid-related signal transduction in advanced Huntington's disease. Exp Physiol. 2001, 86: 683-685. 10.1113/eph8602216.View ArticlePubMedGoogle Scholar
- Katzman M, Cornacchi S, Coonerty-Femiano A, Hughes B, Vermani M, Struzik L, Ross BM: Methyl nicotinate-induced vasodilation in generalized social phobia. Neuropsychopharmacology. 2003, 28: 1846-1851. 10.1038/sj.npp.1300227.View ArticlePubMedGoogle Scholar
- Ross BM, Ward P, Glen I: Delayed vasodilatory response to methylnicotinate in patients with unipolar depressive disorder. J Affect Disord. 2004, 82: 285-290. 10.1016/j.jad.2003.11.005.View ArticlePubMedGoogle Scholar
- Bosveld-van Haandel L, Knegtering R, Kluiter H, Bosch van den RJ: Niacin skin flushing in schizophrenic and depressed patients and healthy controls. Psychiatry Res. 2006, 143: 303-306. 10.1016/j.psychres.2005.10.010.View ArticlePubMedGoogle Scholar
- Shah SH, Vankar GK, Peet M, Ramchand CN: Unmedicated schizophrenic patients have a reduced skin flush in response to topical niacin. Schizophr Res. 2000, 43: 163-164.PubMedGoogle Scholar
- Puri BK, Easton T, Das I, Kidane L, Richardson AJ: The niacin skin flush test in schizophrenia: a replication study. Int J Clin Pract. 2001, 55 (6): 368-370.PubMedGoogle Scholar
- Messamore E, Hoffman WF, Janowsky A: The niacin skin flush abnormality in schizophrenia: a quantitative dose-response study. Schizophr Res. 2003, 62: 251-258. 10.1016/S0920-9964(02)00311-0.View ArticlePubMedGoogle Scholar
- Ross BM, Hughes B, Turenne S, Seeman M, Warsh JJ: Reduced vasodilatory response to methylnicotinate in schizophrenia as assessed by laser Doppler flowmetry. Eur Neuropsychopharmacol. 2004, 14: 191-197. 10.1016/S0924-977X(03)00145-7.View ArticlePubMedGoogle Scholar
- Smesny S, Rosburg T, Riemann S, Baur K, Rudolph N, Berger G, Sauer H: Impaired niacin sensitivity in acute first-episode but not in multi-episode schizophrenia. Prostaglandins Leukot Essent Fatty Acids. 2005, 72: 393-402. 10.1016/j.plefa.2005.02.007.View ArticlePubMedGoogle Scholar
- Lin SH, Liu CM, Chang SS, Hwu HG, Liu SK, Hwang TJ, Hsieh MH, Guo SC, Chen WJ: Familial aggregation in skin flush response to niacin patch among schizophrenic patients and their nonpsychotic relatives. Schizophr Bull. 2007, 33: 174-182. 10.1093/schbul/sbl038.PubMed CentralView ArticlePubMedGoogle Scholar
- Liu CM, Chang SS, Liao SC, Hwang TJ, Shieh MH, Liu SK, Chen WJ, Hwu HG: Absent response to niacin skin patch is specific to schizophrenia and independent of smoking. Psychiatry Res. 2007, 152: 181-187. 10.1016/j.psychres.2006.10.002.View ArticlePubMedGoogle Scholar
- Chang SS, Liu CM, Lin SH, Hwu HG, Hwang TJ, Liu SK, Hsieh MH, Guo SC, Chen WJ: Impaired Flush Response to Niacin Skin Patch Among Schizophrenia Patients and Their Nonpsychotic Relatives: The Effect of Genetic Loading. Schizophr Bull. 2008,Google Scholar
- Smesny S, Rosburg T, Klemm S, Riemann S, Baur K, Rudolph N, Grunwald S, Sauer H: The influence of age and gender on niacin skin test results – implications for the use as a biochemical marker in schizophrenia. J Psychiatr Res. 2004, 38: 537-543. 10.1016/j.jpsychires.2004.01.007.View ArticlePubMedGoogle Scholar